ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos57.3 M49.04 M43.28 M44.95 M46.01 M183.29 MInvestigación y desarrollo76.38 M70.92 M53.37 M69.35 M50.13 M243.77 MBeneficio operativo-103.61 M-88.97 M-65.54 M-90.02 M-70.75 M-315.28 MTotal de ingresos no operativos-16.8 M-5.59 M4.73 M12.95 M-26.82 M-14.73 MGastos por intereses, netos de intereses capitalizados31.37 M—————Ingresos no operativos, una vez deducidos los gastos por intereses-43.91 M-3.69 M-229 K3.68 M-16.17 M-16.41 MIngresos/gastos extraordinarios-4.25 M-1.9 M4.96 M9.26 M-10.64 M1.68 MBeneficio antes de impuestos-107.86 M-90.87 M-60.58 M-80.75 M-81.39 M-313.6 MParticipación en los beneficios0———0—Impuestos-325 K88 K-283 K1 000-643 K-837 KParticipación minoritaria0—————Otros ingresos/gastos después de impuestos-569 K-149 K103 K-1.56 M-453 K-2.06 MBeneficio neto antes de actividades interrumpidas-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MOperaciones suspendidas——————Beneficio neto-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-106.86 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MBeneficio básico por acción-1.92-1.68-1.1-1.45-1.41-5.64Beneficio por acción diluido-1.91-1.68-1.1-1.45-1.41-5.64Número medio de acciones ordinarias51.89 M54.24 M54.86 M55.63 M55.46 M220.19 MAcciones diluidas51.89 M54.24 M54.86 M55.63 M55.46 M220.19 MEBITDA-85.61 M-78.19 M-54.76 M-79.67 M-52.05 M-264.67 MEBIT-103.61 M-82.89 M-59.46 M-84.28 M-70.75 M-297.37 MCosto de los ingresos——————Otros costes de producción——————Amortización y depreciación (flujo de caja)18 M4.7 M4.7 M4.6 M18.7 M32.7 M
Ginkgo Bioworks Holdings Inc Class A
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.